miltefosine has been researched along with Carcinoma, Squamous Cell in 7 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, at the highest dosage group in rats, an increase in white blood cell counts (WBC) was observed." | 2.67 | Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. ( Drogendijk, TE; Oosterom, R; Planting, AS; Pronk, LC; Stoter, G; Verweij, J, 1994) |
| "Miltefosine was highly active against the human KB tumour xenograft in nude mice, leading to growth inhibition as well as regression of large established tumours, which suggested that its mode of action was not mediated by the T cell system." | 1.28 | Investigation into the immunological effects of miltefosine, a new anticancer agent under development. ( Hilgard, P; Kampherm, E; Nolan, L; Pohl, J; Reissmann, T, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prieto, MD | 1 |
| Uribe-Restrepo, AF | 1 |
| Arcos, D | 1 |
| Vargas, DA | 1 |
| Mahieu-Renard, L | 1 |
| Richard, MA | 1 |
| Dales, JP | 1 |
| Buscaylet, S | 1 |
| Lagrassa, S | 1 |
| Grob, JJ | 1 |
| Pronk, LC | 1 |
| Planting, AS | 2 |
| Oosterom, R | 1 |
| Drogendijk, TE | 1 |
| Stoter, G | 3 |
| Verweij, J | 3 |
| Gandia, D | 1 |
| Armand, JP | 1 |
| Fu, D | 1 |
| Shi, Z | 1 |
| Wang, Y | 1 |
| Planting, A | 1 |
| van der Burg, M | 1 |
| Hilgard, P | 1 |
| Kampherm, E | 1 |
| Nolan, L | 1 |
| Pohl, J | 1 |
| Reissmann, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
3 trials available for miltefosine and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, | 1994 |
Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male | 1993 |
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colore | 1992 |
4 other studies available for miltefosine and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Case Report: Squamous Cell Carcinoma Referred for Mohs Surgery Found to be Cutaneous Leishmaniasis.
Topics: Antibodies, Protozoan; Antiprotozoal Agents; Carcinoma, Squamous Cell; Diagnosis, Differential; Fema | 2018 |
[Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
Topics: Administration, Topical; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Leg; | 2005 |
Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Design; Drug Resistance; Gene Expression; Gene | 1999 |
Investigation into the immunological effects of miltefosine, a new anticancer agent under development.
Topics: Animals; Antibody Formation; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Immuni | 1991 |